BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 111 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $290,000 | – | 9,581 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
| NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
| MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
| Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
| RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
| Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
| Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
| Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |